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Abstract
Cytochrome P450 1B1 (CYP1B1) converts xenobiotics to carcinogens and how life-
style choices may interact with CYP1B1 polymorphisms and affect prostate cancer
risk was assessed. Blood genomic DNA from a Caucasian population was analysed
at polymorphic sites of the 50 untranslated region of CYP1B1 using TaqMan geno-
typing assays. Overall, drinker status and minor alleles at rs2551188, rs2567206
and rs10175368 were associated with prostate cancer. Linkage was observed
between rs2551188, rs2567206, rs2567207 and rs10175368, and the G-C-T-G
haplotype (major allele at respective sites) was decreased in cancer. Interestingly
when classified by lifestyle factors, no associations of genotypes were found for
non-smokers and non-drinkers, whereas on the contrary, minor type at rs2567206
and rs10175368 increased and major G-C-T-G decreased risk for cancer among
smokers and drinkers. Interestingly, rs2551188, rs2567206 and rs10175368 minor
genotypes correlated with increased tissue CYP1B1 as determined by immunohisto-
chemistry. Further, rs10175368 enhanced luciferase activity and mobility shift show
stronger binding of nuclear factor for the minor allele. These results demonstrate
smoking and alcohol consumption to modify the risks of CYP1B1 polymorphisms for
prostate cancer which may be through rs10175368, and this is of importance in
understanding their role in the pathogenesis and as a biomarker for this disease.
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1 | INTRODUCTION
Worldwide, prostate cancer ranks second in incidence rates and fifth
in deaths from cancer among men.1 In the United States however,
rates are dramatically high, ranking first in incidence with an esti-
mated 164 690 new cases and second in deaths with 29 430
expected.2 The probability of developing invasive cancer increases
with age from 0.2% in men 49 years or less, 1.7% (50-59 years),
4.8% (60-69 years) and 8.2% (≥70 years). Despite being a disease of
high morbidity and mortality, the cause is not well understood andKato and Hashimoto contributed equally to the work.
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identifying risks in the carcinogenesis process is an important step
towards its prevention.
Lifestyle factors such as tobacco smoking and alcohol consump-
tion are established risks for various types of cancers.3,4 Worldwide,
tobacco smoking accounts for roughly 21% of cancer deaths with
29% in high-income countries.3 In the USA in the year 2010, the
estimated death rate of all cancers due to cigarette smoking was
roughly 38% with about 112 000 deaths among men aged 35 years
or older and does not include additional deaths from environmental
tobacco smoke or usage of cigars, pipes or smokeless tobacco.5 In
prostate, a meta-analysis of 4 million cohort participants showed
that current cigarette smoking was correlated with increased risk of
cancer death (relative risk [RR]; 1.24, 95% confidence interval [CI];
1.18–1.31) with cigarettes smoked per day having a dose-response
association with cancer mortality.6 Also, compared with non-smo-
kers, former smokers (hazard ratio [HR]; 1.63, 95% CI; 1.30–2.04,
P < .001) and current smokers (HR; 1.80, 95% CI 1.45–2.24,
P < .001) had a higher risk of prostate cancer biochemical
recurrence.7
Alcohol consumption accounts for about 5% of all cancer deaths
worldwide and a large proportion of cancers in Europe and America.3
In the USA, 92% of respondents 18 years and older claimed life-time
alcohol usage8 and up to 3.7% of cancer deaths were linked to
drinking in the USA.9 In a meta-analyses study, Bagnardi et al4 find
alcohol drinking to be associated with various cancers and this effect
is strongest among heavy drinkers. The effect of alcohol drinking
appears to be dose-dependent as light to moderate drinking resulted
in a lower risk, whereas heavy drinking caused an increased risk of
certain cancers.10 As for prostate, a dose-response was also
observed for cancer risk among current drinkers (Ptrend < .01).
11
Tobacco smoking and alcohol thus play a causative role in the
carcinogenesis process, and a major enzyme that affects this process
is cytochrome P450 (CYP) 1B1. CYP1B1 is a member of the CYP
superfamily involved in phase I metabolism of many xenobiotics.12,13
CYP1B1 can metabolically convert tobacco smoke pro-carcinogens
such as polycyclic aromatic hydrocarbons to reactive or carcinogenic
intermediates13,14 and result in DNA adduct formation.14,15 In pros-
tate, mRNA transcripts including CYP1B1 were observed along with
DNA adducts after incubating with 2-amino-1-methyl-6-phenyli-
miazo[4,5-b]pyridine (PhIP), 2-amino-3-methylimidazo[4,5-f]quinoline
(IQ) and benzo[a]pyrene (B[a]P).14 Also in primary mammary epithe-
lial cells, B[a]P caused DNA adducts to form as well as CYP1B1
induction.15 Alternatively, PAHs or smoking can enhance levels of
CYP1B1 expression.13,16 As CYP1B1 is expressed in human pros-
tate,17 gene up-regulation and activation of pro-carcinogens may
thus be influential in the prostatic carcinogenesis process.
The main form of alcohol in alcoholic beverages is ethanol, which
may pose a risk even at moderate drinking amounts.18 Levels of
ethanol in blood were shown to dramatically rise above 15 mmol/L
within 30 minutes after drinking whisky (0.72 g/kg ethanol) and
gradually decreased over a 6 hour period.19 Although the tumori-
genicity of ethanol itself may be dependent on experimental condi-
tions, its direct metabolic product acetaldehyde has been shown to
be carcinogenic in animals.20 Indeed, CYP1B1 was shown to metabo-
lize ethanol into significant amounts of acetaldehyde21 and studies
in rats show inhalation and oral administration of acetaldehyde to be
carcinogenic in animals.22,23 Acetaldehyde can interfere with DNA
synthesis and repair,24 cause point mutations,20,24 form direct bonds
with DNA24 and form other DNA adducts at cellular concentra-
tions.24,25 The International Agency for Research on Cancer (IARC)
has listed acetaldehyde as carcinogenic.18 Additionally, acetaldehyde
gets metabolized into acetate via acetaldehyde dehydrogenase and
in the process, radicals are formed24 that can bind to DNA.26
It is thus apparent that CYP1B1 can lead to cancer by activating
various compounds into carcinogenic forms and of interest are
genetic polymorphisms that can alter enzyme levels. A number of
studies have focused on the coding region or missense variants that
enhance CYP1B1 catalytic activity and show them to be associated
with prostate cancer.27,28 Also of importance are variants in the pro-
moter or 50 untranslated region (50UTR) as these may lead to an up-
regulation29 or down-regulation30 of RNA transcription and conse-
quentially, enzyme expression levels. A study on promoter polymor-
phisms and prostate cancer did indeed show variants to be
associated with progression of cancer.31 Promoter polymorphisms
may thus be indicators of disease susceptibility or factors in poly-
genic diseases due to alterations in enzyme expression.
To date, studies on polymorphic variants of the CYP1B1 pro-
moter region/50UTR and their risks for prostate cancer and their
functional role are lacking. Additionally, the impact of lifestyle factors
on the risks of these variants for prostate cancer has never been
investigated. In this report, we evaluated the risks of 8 polymorphic
sites in the promoter region/50UTR of CYP1B1 for prostate cancer
and how this is influenced by major lifestyle factors among a Cau-
casian population. We have been suggested that minor genotypes
and alleles are associated with cancer and that tobacco smoking or
alcohol consumption can increase their risk. Also, we examined the
functional effects of polymorphisms and have been suggested that
minor alleles can affect promoter activity as well as correlate with
protein expression in prostatic cells.
2 | MATERIAL AND METHODS
2.1 | Subjects and specimens
The population study consisted of Caucasian men from the North-
east region of the USA. From these subjects, blood DNA was pro-
cured by the biorepository of Bioserve (Beltsville, MD). All men gave
written informed consent for research purposes. The signed forms
and patient records are kept at the collecting medical institution,
with BioServe never receiving or maintaining any personal health
information with the identity of the donor. Donor samples were
completely anonymized. At the laboratory in San Francisco, speci-
mens and de-identified patient data were obtained from Bioserve
and used for analyses. Characteristics of subjects included in the
case-control study are summarized in Table 1. A total of 400 sam-
ples were obtained from patients with sporadic prostate cancer.
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Stage of prostate cancer was according to the American Joint Com-
mittee on Cancer (AJCC) classification (https://www.ncbi.nlm.nih.
gov/pubmedhealth/PMH0032726/). To assess risks for prostate
cancer, specimens were also obtained from 405 men identified as
healthy. From all specimens, additional information regarding lifestyle
choices was obtained: Smoker is identified as those who currently
smoke or are former smokers, and drinker is those who recognize
themselves as drinker of alcohol. All patients with prostate cancer
and healthy volunteers were thus of the same race (Caucasian), sex
(male), age-matched and from the same region within the USA.
In addition, for CYP1B1 expression analyses, 83 samples of
benign prostatic hyperplasia (BPH) were collected from the Depart-
ment of Anatomy and Pathology at the Veterans Affairs Medical
Center in San Francisco. Specimens are formalin-fixed paraffin-
embedded and de-identified data attached to patients were
obtained. Patients include 51 Caucasians, 14 African-Americans, 10
Asians, 1 Hispanic, 1 native Hawaiian and 6 of unknown race. Aver-
age age  SD of these patients was 68.18  8.13 years (range 41
to 87).
This study was approved by the Clinical Research Office of the
San Francisco Veterans Affairs Medical Center and the Institutional
Review Board of the University of California at San Francisco.
2.2 | CYP1B1 genotyping
To analyse CYP1B1 polymorphisms, TaqMan genotyping assays
(Applied Biosystems, Foster City, CA) were utilized according to manu-
facturer’s instructions. In brief, a 5-lL reaction containing TaqMan
Universal Master Mix (Applied Biosystems) and 0.5 ng of sample DNA
was prepared. Thermal cycle conditions were 95°C for 10 minutes,
followed by 40 to 60 cycles of 95°C for 15 seconds and 60°C for
1 minute. End-point fluorescent readings were analysed using the
QuantStudio 7 Real-Time PCR system (Applied Biosystems). The poly-
morphic sites analysed were in the promoter region/50UTR of the
CYP1B1 gene which were reported in dbSNP (http://www.ncbi.nlm.
nih.gov/projects/SNP/) and ID# (base change, distance prior to ATG
start site) are as follows: rs2551188 (G to A, 263 bp), rs2567206 (C
to T, 1001 bp), rs2567207 (T to C, 1112 bp), rs162556 (T to C, 3
924 bp), rs10175368 (G to A, 5331 bp), rs163090 (T to A, 11
102 bp), rs162330 (T to G, 16966 bp) and rs162331 (A to G, 170
64 bp).
2.3 | Cell culture
Caucasian prostate cancer PC3 and DU145 cell lines were obtained
from American Type Cell Collection (ATCC, Manassas, VA, USA).
Cells were cultured in RPMI1640 medium supplemented with 10%
foetal bovine serum in a humidified atmosphere containing 5% CO2.
These cell lines were authenticated by DNA short-tandem repeat
analysis by ATCC, and experiments with cell lines were performed
within 6 months of their revival.
2.4 | Immunohistochemical analysis
Immunostaining of CYP1B1 was performed on specimens of BPH.
Slides consisting of 4 lm slices of tissue underwent the protocol of
the UltraVision Detection System (Thermo Fisher Scientific, Wal-
tham, MA) according to manufacturer’s instructions. After 12-hour
incubation with rabbit monoclonal antibody for CYP1B1 (1:500 dilu-
tion, #ab185954, Abcam, Cambridge, UK), 3, 30-diaminobenzidine
TABLE 1 Patient characteristics of case-control study. Values expressed as mean  SD
Control (n = 405) Prostate cancer (n = 400) P-value Method
Age (y) 68.3  4.9 68.9  3.8 .188 Student t test
Range (y) 59-80 44-91
BMI 26.7  8.1 27.1  4.1 .107 Mann-Whitney U test
Smoking status
Non-smoker 161 (39.8%) 137 (34.3%) .109 Chi-square
Current or former smoker 244 (60.2%) 263 (65.8%)
Alcohol consumption
Non-drinker 217 (53.6%) 175 (43.8%) .006 Chi-square
Drinker 185 (45.7%) 222 (55.5%)
Unknown 3 (0.7%) 3 (0.7%)
Stage
I 97 (24.3%)
II 156 (39.0%)
III 53 (13.3%)
IV 12 (3.0%)
Unknown 82 (20.5%)
P < .05 are in bold.
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(DAB) was added as chromogen followed by counterstaining with
haematoxylin. Cellular expression levels were analysed by the inten-
sity of positive cells using ImageJ software (http://rsb.info.nih.gov/ij)
and ranked on an overall scale from 0 to 3, with 0 indicating the
absence of staining; 1, weak staining; 2, moderate staining; and 3,
strong staining.
2.5 | Site-directed mutagenesis and promoter
reporter assay
Two sets of Gaussia luciferase CYP1B1 vectors consisting of the
50UTR or promoter region at the following base pairs prior to the
ATG start site: 1143 to +190 and customized 5590 to 5090
were utilized along with negative control (Gene Copoeia, Rockville,
MD). These underwent site-directed mutagenesis using QuikChange
‖ XL Site-Directed Mutagenesis Kit (Agilent technologies, Santa
Clara, CA) according to manufacturer’s protocol. For the 1143 to
+190 region vector, primer sequences for mutagenesis included
rs2551188 sense, 50-GGTGTCCCCAGAACTACGCTCGGTACAAC-30
and antisense, 50-GTTGTACCGAGCGTAGTTCTGGGGACACC-30; and
rs2567206 sense, 50-CACCCTCGGCTGTGCACGCACAGTC-30 and
antisense, 50-GACTGTGCGTGCACAGCCGAGGGTG-30. In vector
containing the 5590 to 5090 region, mutagenesis primers were
rs10175368 sense, 50-GATGTATCTTAGAGTCAATGATGCAATTATA
ATTGGTAGCTTCCTTT-30 and antisense, 50-AAAGGAAGCTACCAATT
ATAATTGCATCATTGACTCTAAGATACATC-30. Mutagenesis was
amplified by pfu HF DNA polymerase using thermal cycling conditions
of 95°C for 1 minute, followed by 18 cycles of 95°C (1 minute), 55°C
(1 minute) and 68°C (20 minutes), then 68°C for 7 minutes. Amplified
product was exposed to Dpn I at 37°C for 1 hour, and the nicked
mutant plasmid DNA was transformed into XL10-Gold Ultracompe-
tent cells for repair. Plasmids were then checked for accuracy by
DNA sequencing (TACGen, San Pablo, CA). The FASTA sequences
and polymorphism information were obtained from the NCBI.
DU145 and PC3 cells in 96-well plates were transfected with
100 ng of reporter gene DNA constructs using Lipofectamine 2000
reagent (Invitrogen). After 72 hours, secreted Gauccia and alkaline
phosphatase (ALP) luciferase activities were determined using the
Detects Gauccia luciferase and secreted Alkaline phosphatase kit
(Gene Copoeia) according to manufacturer’s instructions and VictorTM
X2 luminometer (Perkin Elmer, Waltham, MA). Activity levels of
Gauccia were normalized to ALP.
2.6 | Detection of DNA-protein complex
Nuclear extract was collected from DU145 cells using NE-PER Nuclear
and Cytoplasmic Extraction Reagents kit (Thermo Fisher Scientific)
according to manufacturer’s protocol. To determine the binding capabil-
ity of the nuclear component, extracts (5 lg) along with biotin-labelled
(40 fmol) with and without unlabelled (4 pmol) oligonucleotide probe
were incubated at room temperature for 20 minutes. Oligonucleotide
probe sequences were as follows: rs10175368 (major allele sense, 50-T
TATAATTGCATCATCGACTCTAAGATACA-30 and anti-sense, 50-AAT
ATTAACGTAGTAGCTGAGATTCTATGT-30; minor allele sense, 50-TT
ATAATTGCATCATTGACTCTAAGATACA-30 and anti-sense, 50-AATA
TTAACGTAGTAACTGAGATTCTATGT-30). Probes were annealed in
TEN buffer by gradually decreasing temperature from 95 to 25°C using
thermal cycler prior to adding to reaction mixture. DNA-protein com-
plexes were separated on 6% DNA retardation gel (Invitrogen), blotted
onto Biodyne B Pre-Cut modified nylon membranes (0.45 lm, Thermo
Fisher Scientific) and visualized by ChemiDoc XRS+ system (Bio-Rad,
Hercules, CA).
2.7 | Statistical analyses
For genotypic differences, multiple logistic regression analyses
adjusting for age, body mass index (BMI) and smoker and/or drinker
status were calculated for adjusted odds ratio (OR) and 95% confi-
dence intervals (CI) along with Wald’s test, using R package, epiDis-
play (https://CRAN.R-project.org/package=epiDisplay). Allelic
distributions were analysed by Fisher’s exact test and OR (95% CI)
calculated using the IBM SPSS Statistics version 23 software (IBM,
Armonk, NY). Linkage disequilibrium between locations was mea-
sured in healthy control samples, and haplotype frequency differ-
ences were calculated using SNPAlyze version 6.6.1 software
(DYNACOM; Tokyo, Japan). Hardy-Weinberg equilibrium was also
determined for each site among healthy controls.
Differences in protein expression levels were analysed by two-
tailed Mann-Whitney U test, whereas for luciferase reporter, two-
tailed Student t and Dunnett t tests were utilized. Also, differences
in patient characteristics were analysed by the following: age—two-
tailed Student t test, BMI—two-tailed Mann-Whitney U test, smoker
status—chi-square test and alcohol drinker status—chi-square test.
Analyses were carried out at least in triplicate, and P < .05 was
considered statistically significant.
3 | RESULTS
3.1 | Lifestyle choices and prostate cancer risk
Risks of prostate cancer for patient characteristics such as age, BMI,
smoker status and alcohol drinker status are shown in Table 1. Alco-
hol consumption was observed to be a risk for cancer with 55.5% of
drinkers developing cancer compared to 45.7% without this disease
(P = .006). No associations were observed for age, BMI or smoker
status.
3.2 | CYP1B1 polymorphisms and prostate cancer
risk
Table 2 shows the genotypic and allelic frequencies for the 8 poly-
morphic sites of the CYP1B1 gene analysed in prostate cancer and
healthy controls. Genotypic frequencies at all sites with exception of
rs2567207 are in agreement with the Hardy-Weinberg equilibrium
(data not shown). Interestingly in this Caucasian population, the
minor genotype at rs2567206 (P = .025) and rs10175368 (P = .004)
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for a dominant pattern was observed to be a significant risk for
prostate cancer. The adjusted OR for C/T+T/T compared with major
genotype C/C was 1.38 with a 95% CI of 1.04 to 1.83 for
rs2567206 and at rs10175368, G/A+A/A compared with major G/G
had an adjusted OR of 1.52 with 95% CI of 1.14 to 2.02. Likewise,
the minor allele T and A were also observed to be significantly
increased in PC at rs2567206 (P = .008) and rs10175368 (P = .001),
respectively. Additionally, minor allele A at rs2551188 proved to be
a risk for cancer (P = .043). No differences were found between
patients with prostate cancer and control at other polymorphic sites.
3.3 | Linkage disequilibrium of CYP1B1
polymorphisms
Linkage between the polymorphic sites of CYP1B1 was calculated
and Table 3 shows R2-values among healthy controls. Two sets of
polymorphic sites were observed to be in linkage disequilibrium. One
group consisted of 4 sites (rs2551188, rs2567206, rs2567207 and
rs10175368) and the other with 3 (rs163090, rs162330 and
rs162331). No linkages were observed for rs162556.
3.4 | Haplotype frequencies of CYP1B1
polymorphic sites
Haplotype frequencies of rs2551188-rs2567206-rs2567207-rs1017
5368 and rs163090-rs162330-rs162331 in patients with prostate can-
cer were calculated and results are shown in Table 4. The major haplo-
type was G-C-T-G for rs2551188-rs2567206-rs2567207-rs10175368,
which was expressed in 70.7% of healthy individuals overall. Interest-
ingly, G-C-T-G represents major allele at the respective rs sites and was
significantly reduced in prostate cancer when compared to other haplo-
types combined (P = .028). For rs163090-rs162330-rs162331, 2 haplo-
types were similarly expressed and predominant, being T-T-G (47.7%)
and A-G-A (46.6%) in overall controls. These haplotypes involving
rs163090, rs162330 and rs162331, however, did not show any signifi-
cant differences between cases and controls.
3.5 | CYP1B1 polymorphisms within clinical stage
of prostate cancer patients
Prostate cancer samples were classified in terms of clinical stage.
There were 82 samples of unknown status. No statistical differences
were observed when classified in terms of stage ≤2 (N = 253) vs ≥3
(N = 65) for all CYP1B1 polymorphic sites (data not shown).
3.6 | Influence of lifestyle factors on risks of
CYP1B1 polymorphisms for prostate cancer
As lifestyle factors can affect risks of prostate cancer, interaction
between choices and CYP1B1 polymorphisms were determined.
Table 5 shows risks of prostate cancer for polymorphisms analysed
separately for smokers and non-smokers. Interestingly among non-
smokers, none of the polymorphic sites were associated with cancer,
whereas in smokers, genotype and allele type at rs2567206 (trend
P = .061 and P = .032, respectively) and rs10175368 (P = .002 and
P = .002, respectively) were risks for prostate cancer. Adjusted OR
(95% CI) compared to major genotype was 1.41 (0.98 to 2.02) for C/
T+T/T at rs2567206 and 1.75 (1.22 to 2.52) for G/A+A/A at
rs10175368. Smoker status, however, did not affect risks of poly-
morphisms for stages of cancer (data not shown).
TABLE 2 Genotypic (dominant pattern) and allelic frequencies of CYP1B1 polymorphisms in healthy control and prostate cancer patients
SNP ID Genotype
Control
n (%)
Cancer
n (%)
Adj ORa
(95% CI)
Wald’s
test Allele
Control
n (%)
Cancer
n (%) OR (95% CI) Fisher’s exact
rs2551188 G/G 226 (55.8) 201 (50.2) Reference
1.23 (0.93-1.63)
0.153 G 612 (75.6) 568 (71.0) Reference
1.26 (1.01-1.58)
0.043
G/A+A/A 179 (44.2) 199 (49.8) A 198 (24.4) 232 (29.0)
rs2567206 C/C 230 (56.8) 192 (48.0) Reference
1.38 (1.04-1.83)
0.025 C 615 (75.9) 560 (70.0) Reference
1.35 (1.08-1.69)
0.008
C/T+T/T 175 (43.2) 208 (52.0) T 195 (24.1) 240 (30.0)
rs2567207 T/T 214 (52.8) 203 (50.7) Reference
1.09 (0.82-1.44)
0.567 T 601 (74.2) 566 (70.8) Reference
1.19 (0.96-1.48)
0.132
T/C+C/C 191 (47.2) 197 (49.3) C 209 (25.8) 234 (29.2)
rs162556 T/T 98 (24.2) 109 (27.3) Reference
0.84 (0.61-1.16)
0.296 T 402 (49.6) 413 (51.6) Reference
0.92 (0.76-1.12)
0.426
T/C+C/C 307 (75.8) 291 (72.8) C 408 (50.4) 387 (48.4)
rs10175368 G/G 242 (59.8) 195 (48.8) Reference
1.52 (1.14-2.02)
0.004 G 630 (77.8) 561 (70.1) Reference
1.49 (1.19-1.87)
0.001
G/A+A/A 163 (40.2) 205 (51.2) A 180 (22.2) 239 (29.9)
rs163090 T/T 100 (24.7) 106 (26.5) Reference
0.91 (0.66-1.25)
0.546 T 415 (51.2) 389 (48.6) Reference
1.11 (0.91-1.35)
0.296
T/A+A/A 305 (75.3) 294 (73.5) A 395 (48.8) 411 (51.4)
rs162330 T/T 101 (24.9) 100 (25.0) Reference
0.99 (0.72-1.37)
0.965 T 410 (50.6) 389 (48.6) Reference
1.08 (0.89-1.32)
0.426
T/G+G/G 304 (75.1) 300 (75.0) G 400 (49.4) 411 (51.4)
rs162331 A/A 92 (22.7) 113 (28.2) Reference
0.77 (0.56-1.07)
0.115 A 403 (49.8) 411 (51.4) Reference
0.94 (0.77-1.14)
0.517
A/G+G/G 313 (77.3) 287 (71.8) G 407 (50.2) 389 (48.6)
aOR adjusted for age, BMI, smoker and drinker status. P < .05 are in bold.
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Alcohol drinker status and its interaction with CYP1B1 polymor-
phisms and cancer risks are shown in Table 6. In non-drinkers, none
of the polymorphic sites were associated for prostate cancer with
the exception for a trend for rs10175368 allele (P = .051). In con-
trast among drinkers, significant associations for cancer was
observed for both genotypic and allelic frequencies at rs2567206
(P = .026 and P = .044, respectively) and rs10175368 (P = .012 and
P = .016, respectively). At rs2567206, adjusted OR (95% CI) com-
pared to major genotype was 1.57 (1.05 to 2.33) for C/T+T/T and at
rs10175368, adjusted OR was 1.66 for G/A+A/A with a 95% CI of
1.12 to 2.47 compared to G/G. No effect on stage of cancer was
observed, however, for the interaction between alcohol and CYP1B1
polymorphism.
Interaction between lifestyle choices and CYP1B1 haplotypes was
also determined. The effect of smoker and drinker status on prostate
cancer risks for haplotype frequencies of rs2551188-rs2567206-
rs2567207-rs10175368 and rs163090-rs162330-rs162331 is shown
in Table 4. Interestingly compared to healthy controls, major G-C-T-G
of rs2551188-rs2567206-rs2567207-rs10175368 was significantly
lower in cancer among smokers (P = .036) with a tendency for drin-
kers (P = .066), whereas no associations were observed in non-smo-
kers and non-drinkers. Lifestyle factors did not influence the risks for
any of the rs163090-rs162330-rs162331 haplotypes.
3.7 | CYP1B1 polymorphisms and protein
expression among BPH specimens
As genotypes and haplotypes were observed to be a risk for pros-
tate cancer, expression level of CYP1B1 protein was evaluated for
all sites. Immunohistochemistry was performed on 83 BPH speci-
mens and scored. Interestingly compared to major genotype, variants
at rs2551188 (P = .015), rs2567206 (P =.016) and rs10175368
(P = .047) were determined to have increased CYP1B1 levels (Fig-
ure 1A). Other polymorphic sites, however, showed no correlations
with CYP1B1 expression (data not shown).
3.8 | CYP1B1 polymorphisms and promoter activity
To assess functional properties, all polymorphic sites were evaluated
for promoter activity by site-directed mutagenesis followed by luci-
ferase activity. Although minor alleles of rs2551188 and rs2567206
had no effect, rs10175368. A significantly up-regulated CYP1B1 pro-
moter activity compared to major allele G in both PC3 and DU145
cells (P < .001, Figure 1B). Other polymorphisms did not affect pro-
moter activity (data not shown).
3.9 | Nuclear extract binding of polymorphic site
Promoter activity was enhanced due to polymorphism, and thus, the
binding capability of nuclear extracts to polymorphic sites was anal-
ysed. Nuclear extract was observed to weakly bind to rs10175368 G
allele motif but interestingly, a 2.1-fold larger amount of protein
bound to the minor A allele form (P = .045, Figure 1C). Binding of
nuclear extracts to motifs of rs2551188 and rs2567206 was not
observed (data not shown).
TABLE 3 Linkage disequilibrium among 8 polymorphisms of CYP1B1 in normal healthy individuals. R2-values shown
SNP ID rs2551188 rs2567206 rs2567207 rs162556 rs10175368 rs163090 rs162330 rs162331
rs2551188
rs2567206 0.8239
rs2567207 0.6488 0.7494
rs162556 0.2756 0.2536 0.2505
rs10175368 0.7407 0.8216 0.6603 0.2308
rs163090 0.1328 0.129 0.0902 0.037 0.1026
rs162330 0.1059 0.118 0.0873 0.0287 0.0906 0.8121
rs162331 0.1145 0.1249 0.1019 0.0476 0.1145 0.8837 0.8689
TABLE 4 Influence of lifestyle choices on frequencies of major
haplotypes of rs2551188-rs2567206-rs2567207-rs1017536 (G-C-T-
G) and rs163090-rs162330-rs162331 (A-G-A and T-T-G) of CYP1B1
between healthy controls and prostate cancer patients. Values
expressed as fraction within group
Category Haplotype Control Cancer P-valuea
Overall G-C-T-G 0.7072 0.6563 .028
T-T-G 0.4773 0.4609 .51
A-G-A 0.4663 0.4895 .35
Non-smoker G-C-T-G 0.6920 0.6563 .35
T-T-G 0.4716 0.4486 .57
A-G-A 0.4780 0.4997 .60
Smoker G-C-T-G 0.7178 0.6567 .036
T-T-G 0.4810 0.4673 .66
A-G-A 0.4586 0.4844 .41
Non-drinker G-C-T-G 0.7112 0.6818 .37
T-T-G 0.4602 0.4797 .59
A-G-A 0.4742 0.4768 .94
Drinker G-C-T-G 0.7016 0.6407 .066
T-T-G 0.4996 0.4523 .18
A-G-A 0.4539 0.4926 .27
aP-value based on chi-square test and represents haplotype vs others
combined within lifestyle group. P < .05 are in bold.
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4 | DISCUSSION
The present study evaluated the risks of CYP1B1 polymorphisms in
the promoter region/50UTR for prostate cancer and the influence of
lifestyle factors in a Caucasian population. Overall, drinking produced
a risk for prostate cancer. This is in concordance with prior studies
that show alcohol consumption to be associated with various forms
of cancer4,10 including prostate,11 and one of the main carcinogenic
factors is acetaldehyde, which is derived from ethanol through
cellular enzymes and CYP1B1 has been shown capable of this con-
version.21 Studies demonstrate acetaldehyde to affect cellular prop-
erties such as DNA synthesis and repair,24 cause DNA mutations
and adducts24,25 and undergo further metabolism to form reactive
radicals that can bind DNA.26 For smokers, although only a near
trend was observed as a risk for prostate cancer in this study
(P = .109), meta-analysis shows a significant correlation for current
smoking.6 A possible reason for the meagre significance may be due
to the lack of information regarding the amount of smoking per
TABLE 5 Distribution of CYP1B1 polymorphisms (dominant pattern and allele) in healthy controls and prostate cancer patients among
non-smokers (A) and current or former smokers (B)
SNP ID Genotype
Control
n (%)
Cancer
n (%)
Adj ORa
(95% CI)
Wald’s
test Allele
Control
n (%)
Cancer
n (%) OR (95% CI)
Fisher’s
exact
A. Non-smokers
rs2551188 G/G 84 (52.2) 63 (46.0) Reference
1.29 (0.81-2.05)
0.288 G 238 (73.9) 187 (68.2) Reference
1.32 (0.92-1.88)
0.146
G/A+A/A 77 (47.8) 74 (54.0) A 84 (26.1) 87 (31.8)
rs2567206 C/C 87 (54.0) 62 (45.3) Reference
1.45 (0.91-2.33)
0.118 C 240 (74.5) 187 (68.2) Reference
1.36 (0.95-1.95)
0.101
C/T+T/T 74 (46.0) 75 (54.7) T 82 (25.5) 87 (31.8)
rs2567207 T/T 81 (50.3) 67 (48.9) Reference
1.10 (0.69-1.75)
0.699 T 233 (72.4) 192 (70.1) Reference
1.12 (0.78-1.60)
0.586
T/C+C/C 80 (49.7) 70 (51.1) C 89 (27.6) 82 (29.9)
rs162556 T/T 42 (26.1) 39 (28.5) Reference
0.95 (0.57-1.60)
0.854 T 167 (51.9) 147 (53.6) Reference
0.93 (0.67-1.29)
0.681
T/C+C/C 119 (73.9) 98 (71.5) C 155 (48.1) 127 (46.4)
rs10175368 G/G 89 (55.3) 68 (49.6) Reference
1.25 (0.78-1.99)
0.352 G 245 (76.1) 192 (70.1) Reference
1.36 (0.65-1.95)
0.114
G/A+A/A 72 (44.7) 69 (50.4) A 77 (23.9) 82 (29.9)
rs163090 T/T 39 (24.2) 33 (24.1) Reference
1.02 (0.59-1.75)
0.949 T 163 (50.6) 128 (46.7) Reference
1.17 (0.85-1.61)
0.366
T/A+A/A 122 (75.8) 104 (75.9) A 159 (49.4) 146 (53.3)
rs162330 T/T 38 (23.6) 34 (24.8) Reference
0.94 (0.55-1.62)
0.829 T 160 (49.7) 132 (48.2) Reference
1.06 (0.77-1.47)
0.743
T/G+G/G 123 (76.4) 103 (75.2) G 162 (50.3) 142 (51.8)
rs162331 A/A 38 (23.6) 40 (29.2) Reference
0.72 (0.42-1.22)
0.223 A 164 (50.9) 145 (52.9) Reference
0.92 (0.66-1.27)
0.681
A/G+G/G 123 (76.4) 97 (70.8) G 158 (49.1) 129 (47.1)
B. Current or Former Smokers
rs2551188 G/G 142 (58.2) 138 (52.5) Reference
1.24 (0.87-1.78)
0.236 G 374 (76.6) 381 (72.4) Reference
1.25 (0.94-1.66)
0.131
G/A+A/A 102 (41.8) 125 (47.5) A 114 (23.4) 145 (27.6)
rs2567206 C/C 143 (58.6) 130 (49.4) Reference
1.41 (0.98-2.02)
0.061 C 375 (76.8) 373 (70.9) Reference
1.36 (1.03-1.80)
0.032
C/T+T/T 101 (41.4) 133 (50.6) T 113 (23.2) 153 (29.1)
rs2567207 T/T 133 (54.5) 136 (51.7) Reference
1.12 (0.78-1.60)
0.549 T 368 (75.4) 374 (71.1) Reference
1.25 (0.94-1.65)
0.136
T/C+C/C 111 (45.5) 127 (48.3) C 120 (24.6) 152 (28.9)
rs162556 T/T 56 (23.0) 70 (26.6) Reference
0.76 (0.50-1.15)
0.191 T 235 (48.2) 266 (50.6) Reference
0.91 (0.71-1.16)
0.451
T/C+C/C 188 (77.0) 193 (73.4) C 253 (51.8) 260 (49.4)
rs10175368 G/G 153 (62.7) 127 (48.3) Reference
1.75 (1.22-2.52)
0.002 G 385 (78.9) 369 (70.2) Reference
1.59 (1.20-2.12)
0.002
G/A+A/A 91 (37.3) 136 (51.7) A 103 (21.1) 157 (59.7)
rs163090 T/T 61 (25.0) 73 (27.8) Reference
0.85 (0.57-1.27)
0.418 T 252 (51.6) 261 (49.6) Reference
1.08 (0.85-1.39)
0.530
T/A+A/A 183 (75.0) 190 (72.2) A 236 (48.4) 265 (50.4)
rs162330 T/T 63 (25.8) 66 (25.1) Reference
1.01 (0.67-1.52)
0.955 T 250 (51.2) 257 (48.9) Reference
1.10 (0.86-1.41)
0.452
T/G+G/G 181 (74.2) 197 (74.9) G 238 (48.8) 269 (51.1)
rs162331 A/A 54 (22.1) 73 (27.8) Reference
0.76 (0.50-1.16)
0.203 A 239 (49.0) 266 (50.6) Reference
0.94 (0.73-1.20)
0.616
A/G+G/G 190 (77.9) 190 (72.2) G 249 (51.0) 260 (49.4)
aOR adjusted for age, BMI, and drinker status. P < .05 are in bold.
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individual and perhaps a breakdown by pack-years may show a sig-
nificant risk among heavy smokers, as a dose-response effect of
smoking was observed for prostate cancer mortality.6 Tobacco
smoke contains numerous compounds that can promote cancer and
agents such as polycyclic aromatic hydrocarbons (PAH) have been
shown to enhance cancer of the lung, bladder, and head and neck.12
Interestingly in prostate cancer tissue, Caucasian ever smokers had
significantly higher PAH-DNA adducts compared to non-smokers.32
When evaluating polymorphic sites of CYP1B1, the minor allele
at rs2551188, rs2567206 and rs10175368 were an overall risk for
prostate cancer. Interestingly when separated by lifestyle choices,
none of these were associated with cancer among non-smokers and
non-drinkers with the exception for a trend for rs10175368 allele
among non-drinkers. These results for men who do not smoke and
drink alcohol are comparable to a study performed on Hispanic and
non-Hispanic Caucasians as no association for prostate cancer was
observed for rs2551188 and rs2567206 by Beuten et al,31 although
breakdown by lifestyle choices was not provided. On the contrary,
smoking and alcohol drinking resulted in the minor alleles and geno-
types at rs2567206 and rs10175368 to be a risk for cancer. Lifestyle
TABLE 6 Distribution of CYP1B1 polymorphisms (dominant pattern and allele) in healthy controls and prostate cancer patients among non-
drinkers (A) and drinkers (B)
SNP ID Genotype
Control
n (%)
Cancer
n (%)
Adj ORa
(95% CI)
Wald’s
test Allele
Control
n (%)
Cancer
n (%)
OR
(95% CI)
Fisher’s
exact
A. Non-drinkers
rs2551188 G/G 123 (56.7) 93 (53.1) Reference
1.15 (0.77-1.73)
0.494 G 333 (76.7) 256 (73.1) Reference
1.21 (0.88-1.67)
0.280
G/A+A/A 94 (43.3) 82 (46.9) A 101 (23.3) 94 (26.9)
rs2567206 C/C 125 (57.6) 92 (52.6) Reference
1.22 (0.81-1.83)
0.339 C 334 (77.0) 255 (72.9) Reference
1.24 (0.90-1.72)
0.213
C/T+T/T 92 (42.4) 83 (47.4) T 100 (23.0) 95 (27.1)
rs2567207 T/T 114 (52.5) 92 (52.6) Reference
1.02 (0.68-1.52)
0.942 T 323 (74.4) 253 (72.3) Reference
1.12 (0.81-1.53)
0.516
T/C+C/C 103 (47.5) 83 (47.4) C 111 (25.6) 97 (27.7)
rs162556 T/T 48 (22.1) 43 (24.6) Reference
0.85 (0.53-1.37)
0.515 T 213 (49.1) 173 (49.4) Reference
0.99 (0.74-1.31)
0.943
T/C+C/C 169 (77.9) 132 (75.4) C 221 (50.9) 177 (50.6)
rs10175368 G/G 133 (61.3) 93 (53.1) Reference
1.40 (0.93-2.11)
0.107 G 344 (79.3) 256 (73.1) Reference
1.40 (1.01-1.95)
0.051
G/A+A/A 84 (38.7) 82 (46.9) A 90 (20.7) 94 (26.9)
rs163090 T/T 49 (22.6) 52 (29.7) Reference
0.68 (0.43-1.08)
0.104 T 218 (50.2) 177 (50.6) Reference
0.99 (0.75-1.31)
0.943
T/A+A/A 168 (77.4) 123 (70.3) A 216 (49.8) 173 (49.4)
rs162330 T/T 47 (21.7) 48 (27.4) Reference
0.69 (0.43-1.11)
0.127 T 214 (49.3) 175 (50.0) Reference
0.97 (0.73-1.29)
0.886
T/G+G/G 170 (78.3) 127 (72.6) G 220 (50.7) 175 (50.0)
rs162331 A/A 50 (23.0) 50 (28.6) Reference
0.78 (0.49-1.25)
0.305 A 224 (51.6) 175 (50.0) Reference
1.07 (0.80-1.41)
0.667
A/G+G/G 167 (77.0) 125 (71.4) G 210 (48.4) 175 (50.0)
B. Drinkers
rs2551188 G/G 101 (54.6) 108 (48.6) Reference
1.32 (0.89-1.96)
0.172 G 274 (74.1) 310 (69.8) Reference
1.23 (0.91-1.68)
0.185
G/A+A/A 84 (45.4) 114 (51.4) A 96 (25.9) 134 (30.2)
rs2567206 C/C 103 (55.7) 100 (45.0) Reference
1.57 (1.05-2.33)
0.026 C 276 (74.6) 302 (68.0) Reference
1.38 (1.02-1.88)
0.044
C/T+T/T 82 (44.3) 122 (55.0) T 94 (25.4) 142 (32.0)
rs2567207 T/T 98 (53.0) 111 (50.0) Reference
1.18 (0.79-1.74)
0.423 T 273 (73.8) 311 (70.0) Reference
1.20 (0.89-1.64)
0.242
T/C+C/C 87 (47.0) 111 (50.0) C 97 (26.2) 133 (30.0)
rs162556 T/T 50 (27.0) 65 (29.3) Reference
0.84 (0.54-1.31)
0.438 T 188 (50.8) 236 (53.2) Reference
0.91 (0.69-1.20)
0.526
T/C+C/C 135 (73.0) 157 (70.7) C 182 (49.2) 208 (46.8)
rs10175368 G/G 107 (57.8) 102 (45.9) Reference
1.66 (1.12-2.47)
0.012 G 281 (75.9) 303 (68.2) Reference
1.45 (1.07-1.98)
0.016
G/A+A/A 78 (42.2) 120 (54.1) A 89 (24.1) 141 (31.8)
rs163090 T/T 51 (27.6) 54 (24.3) Reference
1.19 (0.76-1.86)
0.44 T 195 (52.7) 212 (47.7) Reference
1.22 (0.93-1.61)
0.181
T/A+A/A 134 (72.4) 168 (75.7) A 175 (47.3) 232 (52.3)
rs162330 T/T 54 (29.2) 52 (23.4) Reference
1.37 (0.87-2.13)
0.171 T 194 (52.4) 214 (48.2) Reference
1.19 (0.90-1.56)
0.232
T/G+G/G 131 (70.8) 170 (76.6) G 176 (47.6) 230 (51.8)
rs162331 A/A 41 (22.2) 60 (27.0) Reference
0.75 (0.47-1.18)
0.211 A 175 (47.3) 230 (51.8) Reference
0.84 (0.63-1.10)
0.206
A/G+G/G 144 (77.8) 162 (73.0) G 195 (52.7) 214 (48.2)
aOR adjusted for age, BMI, and smoker status. P < .05 are in bold.
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F IGURE 1 Properties of CYP1B1
promoter polymorphisms. A, CYP1B1
expression in clinical samples.
Representative immunostaining of CYP1B1
by polymorphism status in benign prostatic
hyperplasia (BPH) specimens. (a) None to
weak staining, (b) moderate staining, and
(c) stronger staining. (d) Staining score
categorized by polymorphism status for
rs2551188, rs2567206 and rs10175368.
Score was significantly higher for minor
genotype at rs2551188 (G/A+A/A),
rs2567206 (C/T+T/T) and rs10175368
(G/A+A/A) compared to respective major
genotypes. Number of specimens for each
polymorphic status is indicated in
parentheses. Data expressed as
mean  SD. *P < .05, determined by two-
tailed Mann-Whitney U test. B, Effect of
CYP1B1 polymorphisms on luciferase
activity in prostate cancer cells. PC-3 and
DU145 cells seeded in 96-well plates were
transfected with either CYP1B1 minor or
major allele constructs, and secreted
Gauccia and ALP luciferase activities were
measured. CYP1B1 promoter activities
were calculated as the ratio of Gauccia to
ALP. Levels were significantly higher for
the rs10175368 allele A compared to
major type G. Data expressed as
meanSEM for triplicates. ***P < .001,
determined by Dunnett t (for rs2551188
and rs2567206) and two-tailed Student t
(for rs10175368) tests. C, Binding of
nuclear factor to rs10175368 motif. Left:
Nuclear extract prepared from DU145 cells
was incubated with biotinylated double-
strand oligonucleotide probe for
rs10175368 (5346 to 5317 bp) with or
without unlabelled DNA competitor, and
complex separated by gel electrophoresis.
Arrow denotes protein-bound probe. Right:
Stronger binding of protein factor was
observed for the minor allele A compared
to major allele G. Data expressed as
meanSEM for triplicates. *P = .045, two-
tailed Student t test
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choices can therefore modify the risks of CYP1B1 polymorphisms
for prostate cancer.
Interaction between smoking and CYP1B1 polymorphisms lead-
ing to cancer has been shown in other studies. Harth et al33 anal-
ysed polymorphisms of genes in head and neck cancer and in a
subgroup of non-smokers, variants of the ERCC2 gene were pre-
dominant but when stratifying for smokers, CYP1B1 variant pro-
duced main effect. In lung adenocarcinoma, Rotunno et al34
observed no association for combined rs10175368/rs9341266 vari-
ants in never smokers but among ever smokers, this dual site was
modified to significance. Timofeeva et al35 found that in women, no
association was found for the minor genotype between rs1056836,
rs1056827 and rs2567206 and lung cancer risk among non- and
light smokers, whereas in heavy smokers, increased risk was
observed. In a case-only study of patients with colorectal cancer,
Fan et al36 observed that risks of rs1056836 variant for cancer were
increased in smokers compared to non-smokers.
It is of interest that in a lifestyle choice study analysing 40 candi-
date genes among middle-aged men, a CYP1B1 variant was associ-
ated with habitual alcohol drinking.37 Certainly, alcohol can also
modify risks of variants for cancer as demonstrated by others. In
cancer of the pharynx and larynx, although rs1056836 was a risk in
non-drinkers, odds ratio for the variant was much higher among
drinkers.38 For squamous cell carcinoma of the head and neck, no
association was found for polymorphisms of various genes but when
analysed by potential modifiers, alcohol drinking affected the risks of
CYP1B1 variants.39 In cervical cancer, rs1056836 variant was not a
risk among non-drinkers but among drinkers, a trend (P = .1) towards
risk was observed with an OR value 2-fold greater.40 Likewise in
head and neck cancer, risk of rs10012 and rs1056837 had a crude
OR of 1.6 and 2.3 for heterozygous and homozygous variant,
respectively, but among alcohol drinkers, OR dramatically increased
to 6.1 and 5.2, respectively.41
Linkage was observed among the 3 sites showing a risk for can-
cer along with rs2567207. Haplotype analyses demonstrate the
major G-C-T-G form to be significantly lower in prostate cancer
cases compared to healthy controls. As was the case for individual
polymorphic sites, lifestyle factors appear to interact with haplotype
as G-C-T-G proved to also have reduced risk among smokers and
drinkers but not among abstainers of these choices. Haplotype of
these sites may thus be an indicator of risk in the aetiology of pros-
tate cancer that is influenced by lifestyle factors. Beuten et al31 also
observed linkage between rs2551188 and rs2567206, and haplotype
involving G-C at these respective sites demonstrated a reduced risk
for prostate cancer, which is in agreement with our results.
Polymorphisms of rs2551188, rs2567206 and rs10175368 are
thus determined to be a risk for prostate cancer and the mechanism
by which they may play a role is not known. These sites are located
in the promoter or 50UTR which are of importance as variants in this
region may lead to increased gene expression29 and, consequently,
increased enzyme or CYP1B1 levels. In concordance, results of this
study demonstrate polymorphisms at these 3 sites to be associated
with increased CYP1B1 protein levels as was observed in human
prostatic specimens. On the contrary, only the rs10175368 minor
allele showed increased luciferase activity and mobility shift demon-
strated strong binding towards this variant. As these sites are linked,
it may thus be through the minor allele of rs10175368 that expres-
sion levels of CYP1B1 are increased. This co-dependence with
rs10175368 may be pertinent for rs2567206 as cancer risk for these
sites was modified by smoker and alcohol drinker status. This is cor-
roborated in smokers as Rotunno et al34 observed rs10175368 to
have increased mRNA expression among current smokers (P
= .004) but not for never and former smokers. Thus, these lifestyle
factors appear to interact at the genetic level to possibly increase
CYP1B1 levels with rs10175368 playing a major role. Further experi-
mentation is necessary to determine the identity of the factor that
can bind to the rs10175368 minor allele in prostate cancer cells.
On the other hand, risk of the rs2551188 A allele was not
affected by lifestyle factors and did not affect promoter activity or
bind nuclear protein. Reasons for this independence are not known.
Unlike rs2567206 and rs10175368 that are in the gene promoter
region, rs2551188 is located in the 50UTR of intron 1. This site
undergoes a G to A base change and studies suggest this transition
to affect RNA stability,42 which can consequentially lead to
enhanced processing and gene or CYP1B1 expression. Alternatively,
up-regulation may be caused by linkage with rs10175368.
In conclusion, polymorphisms of the promoter and 50UTR
region of CYP1B1 are determined to be a risk for prostate cancer
that can be modified by lifestyle factors in Caucasian men. These
polymorphisms that potentially are capable of increasing gene
expression levels and more so due to rs10175368 are thus critical
to the prostate cell as CYP1B1 plays a role in the activation of
carcinogens from precursors from various sources such as tobacco
smoke and alcohol. These findings thus suggest CYP1B1 and its
polymorphisms as a potential biomarker and gene of importance
in understanding the pathogenesis of prostate cancer. It is essen-
tial to note, however, that this study does have its limitations as
total sample size consisted of 405 controls and 400 prostate can-
cer cases, and a larger validation study is needed to verify results
in the future.
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